Indivior PLC
General ticker "INDV" information:
- Sector: Health Care
- Industry: Drug Manufacturers - Specialty & Generic
- Capitalization: $4.2B (TTM average)
Indivior PLC follows the US Stock Market performance with the rate: 43.9%.
Estimated limits based on current volatility of 1.1%: low 34.09$, high 34.82$
Factors to consider:
- Total employees count: 838 (-18.6%) as of 2025
- US accounted for 0.3% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Operational and conduct risks, Manufacturing issues, Regulatory and compliance, Litigation risks, Market competition
- Price in estimated range
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [21.96$, 42.76$]
- 2026-12-31 to 2027-12-31 estimated range: [18.35$, 36.48$]
Financial Metrics affecting the INDV estimates:
- Positive: with PPE of 14.7 at the end of fiscal year the price was neutral
- Negative: Operating cash flow per share per price, % of -0.60 <= 2.37
- Positive: 15.80 < Operating profit margin, % of 21.39
- Negative: -0.33 < Industry inventory ratio change (median), % of -0.31
- Negative: Investing cash flow per share per price, % of -1.46 <= -1.23
- Negative: negative Industry operating income (median)
- Negative: negative Industry operating cash flow (median)
- Negative: Shareholder equity ratio, % of -8.16 <= 7.04
- Negative: -3.92 < Inventory ratio change, % of -2.04
Short-term INDV quotes
Long-term INDV plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $854.00MM | $1,188.00MM | $1,239.00MM |
| Operating Expenses | $1,006.00MM | $1,156.00MM | $974.00MM |
| Operating Income | $-152.00MM | $32.00MM | $265.00MM |
| Non-Operating Income | $7.00MM | $-18.00MM | $-26.00MM |
| Interest Expense | $35.00MM | $41.00MM | $45.00MM |
| R&D Expense | $116.00MM | $107.00MM | $97.00MM |
| Income(Loss) | $-145.00MM | $14.00MM | $239.00MM |
| Taxes | $-19.00MM | $11.00MM | $29.00MM |
| Net Income(Loss)* | $-129.00MM | $2.00MM | $210.00MM |
| Stockholders Equity | $-191.00MM | $-337.00MM | $-98.00MM |
| Inventory | $135.00MM | $178.00MM | $153.00MM |
| Assets | $1,760.00MM | $1,316.00MM | $1,201.00MM |
| Operating Cash Flow | $-300.00MM | $36.00MM | $-27.00MM |
| Capital expenditure | $53.00MM | $31.00MM | $67.00MM |
| Investing Cash Flow | $-95.00MM | $69.00MM | $-66.00MM |
| Financing Cash Flow | $-64.00MM | $-102.00MM | $-30.00MM |
| Earnings Per Share** | $-0.94 | $0.02 | $1.68 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.